A 14‐Year Study of Serum Glial Fibrillary Acidic Protein and Total Tau in Premanifest Huntington's
Year: 2025
Type: article
Study design: Observational Study
Abstract: There is a pressing need for blood biomarkers that can identify Huntington's disease (HD) gene carriers' proximity to manifest disease. We previously examined serial serum neurofilament light (NfL) concentrations in 21 premanifest HD gene carriers and 14 controls over 14 years, finding that NfL demonstrates high prognostic value and distinct longitudinal dynamics in premanifest/transitional HD. Here, we report the corresponding results for serum glial fibrillary acidic protein and total tau, providing the first longitudinal and head-to-head study of these biomarkers in HD. Our findings do not support the utility of these analytes as prognostic biomarkers in premanifest and transitional HD.
DOI: 10.1002/acn3.70057
Authors: Natalia E. Owen, Zanna J. Voysey, Jonathan A. Holbrook, Maura Malpetti, Clara Le Draoulec, Lennart R. B. Spindler, Anna O. G. Goodman, Alpar S. Lazar, Roger A. Barker
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,100
Awards: G139696651, Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’, Cambridge Stem Cell Institute, G2781699360, G299057155, G3078855993, G3584577881, G370598735, G4637052155, G5484725842, G6077662935, G6641991021, Cambridge Stem Cell Institute, G7826725679, G8872004867, G9000171483, Cambridge Stem Cell Institute
OpenAlex ID: W4409647713